The price of Novan Inc. (NASDAQ:NOVN) shares last traded on Wall Street fell -6.44% to $0.17.
Based on available information, 1 analysts follow Novan Inc. (NASDAQ:NOVN). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $14.00, we find $14.00. Given the previous closing price of $0.18, this indicates a potential upside of 7677.78 percent. NOVN stock price is now -80.14% away from the 50-day moving average and -85.74% away from the 200-day moving average. The market capitalization of the company currently stands at $4.33M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $14.00 as their price target over the next twelve months.
With the price target of $30, Cantor Fitzgerald recently initiated with Overweight rating for Novan Inc. (NASDAQ: NOVN).
In other news, SANDERS MACHELLE, Director sold 11,553 shares of the company’s stock on Jun 27. The stock was sold for $4,716 at an average price of $0.41. Upon completion of the transaction, the Director now directly owns 25,248 shares in the company, valued at $4292.16. Insiders disposed of 20,669 shares of company stock worth roughly $3513.7300000000005 over the past 1 year. A total of 0.45% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NOVN stock. A new stake in Novan Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $378,000. TWO SIGMA SECURITIES, LLC invested $7,000 in shares of NOVN during the first quarter. In the first quarter, DRW SECURITIES, LLC acquired a new stake in Novan Inc. valued at approximately $3,000. In total, there are 38 active investors with 18.90% ownership of the company’s stock.
A candlestick chart of Novan Inc. (NASDAQ: NOVN) showed a price of $0.1572 on Tuesday morning. During the past 12 months, Novan Inc. has had a low of $0.15 and a high of $3.33. The fifty day moving average price for NOVN is $0.8289 and a two-hundred day moving average price translates $1.1719 for the stock.
The latest earnings results from Novan Inc. (NASDAQ: NOVN) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.54, missing analysts’ expectations of -$0.32 by -0.22. This compares to -$0.71 EPS in the same period last year. The company reported revenue of $3.17 million for the quarter, compared to $1.93 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 64.21 percent. For the current quarter, analysts expect NOVN to generate $6.33M in revenue.
Novan Inc.(NOVN) Company Profile
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, Novan, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
